Nemluvio (Nemolizumab) for Eczema

Overview
Nemluvio is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe atopic dermatitis (the most common form of eczema) in adults and children ages 12 years and older. It is prescribed when eczema is not adequately controlled with topical prescription therapies. Nemluvio is used in combination with topical corticosteroids and/or calcineurin inhibitors. Nemluvio is also known by its drug name, nemolizumab-ilto.

Nemluvio works by blocking the interleukin (IL)-31 receptor, which plays a role in the itch and inflammation associated with eczema. By inhibiting this receptor, Nemluvio helps reduce symptoms such as itching and skin irritation.

How do I take it?
Prescribing information states that Nemluvio is administered as a subcutaneous (under the skin) injection. The recommended dosing schedule starts with two injections, followed by a maintenance dose of one injection every four weeks. After 16 weeks of treatment, if a person achieves clear or almost clear skin, the dose may be reduced to one injection every eight weeks.

Nemluvio is used alongside topical corticosteroids and/or calcineurin inhibitors. These topical therapies may be discontinued once the disease sufficiently improves. Nemluvio must be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Nemluvio include headache (including migraine headaches), arthralgia (joint pain), urticaria (hives), and myalgia (muscle pain).

Rare but serious side effects may include hypersensitivity reactions. Signs of hypersensitivity may include difficulty breathing, swelling of the face or throat, and severe itching. If any of these symptoms occur, treatment should be stopped immediately, and medical care should be sought.

For more information about this treatment, visit:

Nemluvio (Nemolizumab-Ilto) for Injection, for Subcutaneous Use — Galderma